Therapeutic Approach

Archive: June, 2013

Ritter Pharmaceuticals’ Study Shows That Altering The Intestinal Microbiome May Offer An Effective Treatment for Lactose Intolerance

Data presented at New York Academy of Sciences LOS ANGELES, Calif., June 12, 2013 — Ritter Pharmaceuticals announced that data from its Phase 2 clinical study of RP-G28, in patients with lactose intolerance demonstrated the agent’s ability to alter the composition of microbes in patient’s intestines. The work was presented at the New York Academy […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD